Verastem: Strong Study Data and Over 200% Price Potential Electrify Wall Street

Successful Market Launch and Positive Company Outlook Verastem Inc. (VSTM) is currently in a crucial growth and consolidation phase, significantly driven by recent business figures and the successful marketing of the combination therapy AVMAPKI FAKZYNJA. From the corporation's perspective, the last quarters have been extremely gratifying, as evidenced by a notable increase in product sales to $17.5 million in Q4 2025. Management is highly optimistic about the future and communicates a clear strategic goal that the entire business segment for...